Kaken Pharmaceutical Co (KKPCF) Stock Price & Analysis

KKPCF Stock Chart & Stats

$24.74$0.11(0.47%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $22.68 - $26.80
52-Week Range: $20.68 - $30.84
Previous Close: $24.63
Volume: 200
Average Volume (3M): 0
Market Cap: $873.90M
Enterprise Value: $91.72B
Total Cash (Recent Filing): $55.40B
Total Debt (Recent Filing): $3.85B
Price to Earnings (P/E): 14.1
Beta: 0.08
Next Earnings: Nov 09, 2026 (Est.)
EPS Estimate: -0.03
Next Dividend Ex-Date: Mar 30, 2027
Dividend Yield: 4.85%

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage and a large equity base reduce refinancing risk and provide flexibility to sustain R&D, support commercialization, or absorb periods of weaker earnings without balance-sheet strain.

Specialty Pharmaceutical Focus

A focused specialty portfolio and internal R&D platform can support differentiated products, specialized commercial expertise, and stronger customer relationships than a broadly undifferentiated drug portfolio.

Established Domestic Commercial Model

An established prescription-drug platform gives Kaken access to recurring physician-led demand and Japan’s reimbursement system, while its salesforce and commercial operations support ongoing product monetization.

Bears Say

Sharp Revenue Contraction

The substantial revenue decline indicates pressure on product demand, lifecycle performance, or market conditions. Sustained contraction would weaken operating leverage and reduce the resources available for future pharmaceutical development.

Negative Cash Generation

A reversal to operating and free cash outflow raises earnings-quality and working-capital concerns. If cash generation does not normalize, internal funding for R&D, launches, and shareholder returns could become less flexible.

Profitability And ROE Deterioration

The steep margin and return decline shows that the current product mix or cost base is not converting revenue efficiently. Persistently weak profitability would reduce the economic value of the company’s R&D and asset base.

Kaken Pharmaceutical Co News

Kaken Pharmaceutical Swings to Strong Profit but Suspends Dividend Despite Sales Surge

An announcement from Kaken Pharmaceutical Co ( ($JP:4521) ) is now available. Kaken Pharmaceutical reported strong top-line growth for the three months ended June 30, 2026, with net sales climbing

2M agoKKPCF 4521

KKPCF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Kaken Pharmaceutical Co (KKPCF) is scheduled to report 4th quarter earnings on 05/13/2026. Regarding Q4 estimates, Wall Street analysts expect Kaken Pharmaceutical Co to post earnings of Yen19.99 per share.

5M agoKKPCF 4521

Kaken’s KP-001 Phase 3 Trial Targets Rare Vascular Disorders, Adding Long-Term Upside to KKPCF

Kaken Pharmaceutical Co ($KKPCF) announced an update on their ongoing clinical study. Study Overview: Kaken Pharmaceutical has launched a phase 3 trial to test KP-001 in patients aged two and

10M agoKKPCF

Kaken Pharmaceutical initiated with a Neutral at UBS

UBS initiated coverage of Kaken Pharmaceutical (KKPCF) with a Neutral rating and 4,200 yen price target he firm says the company’s business stability is priced into the shares with limited

10M agoKKPCF 4521

KKPCF FAQ

What was Kaken Pharmaceutical Co’s price range in the past 12 months?

Kaken Pharmaceutical Co lowest stock price was $20.68 and its highest was $30.84 in the past 12 months.

What is Kaken Pharmaceutical Co’s market cap?

Kaken Pharmaceutical Co’s market cap is $873.90M.

When is Kaken Pharmaceutical Co’s upcoming earnings report date?

Kaken Pharmaceutical Co’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 7 days.

How were Kaken Pharmaceutical Co’s earnings last quarter?

Kaken Pharmaceutical Co released its earnings results on Aug 07, 2026. The company reported $1.412 earnings per share for the quarter.

Is Kaken Pharmaceutical Co overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Kaken Pharmaceutical Co pay dividends?

Kaken Pharmaceutical Co pays a Semiannually dividend of $0.602 which represents an annual dividend yield of 4.85%. See more information on Kaken Pharmaceutical Co dividends here

What is Kaken Pharmaceutical Co’s EPS estimate?

Kaken Pharmaceutical Co’s EPS estimate is -0.03.

How many shares outstanding does Kaken Pharmaceutical Co have?

Kaken Pharmaceutical Co has 44,139,730 shares outstanding.

What happened to Kaken Pharmaceutical Co’s price movement after its last earnings report?

Kaken Pharmaceutical Co reported an EPS of $1.412 in its last earnings report. Following the earnings report the stock price went up 1.921%.

Which hedge fund is a major shareholder of Kaken Pharmaceutical Co?

Currently, no hedge funds are holding shares in KKPCF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kaken Pharmaceutical Co

Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.

Kaken Pharmaceutical Co (KKPCF) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	13	6	3
Technical Analysis	3	6	1
Moving Averages	10	0	2

Technical Analysis >

Similar Stocks

Stocks similar to KKPCF
Company	Price & Change	Follow
JP:4547Kissei Pharmaceutical Co
JP:4553Towa Pharmaceutical Co
JP:4534Mochida Pharmaceutical Co., Ltd.
JP:4569KYORIN Pharmaceutical Co.,Ltd.
JP:4887SAWAI GROUP HOLDINGS Co., Ltd.

Compare KKPCF Stocks >

Ownership Overview

3.72% Mutual Funds
91.99% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft